Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?
Table 5
The evolution of hesitancy and terminal dribbling.
Hesitancy
Terminal dribbling
Variable
Baseline n (%) [B]
Week 1 n (%) [W1]
Week 6 n (%) [W6]
Statistical analyses inside each group
Baseline n (%) [B]
Week 1 n (%) [W1]
Week 6 n (%) [W6]
Statistical analyses inside each group
Control group (n=110) C
11 (10)
45 (40.9)
29 (26.4)
B vs W1 chi2=27.7 p<0.001 B vs W6 chi2= 9.9 p=0.017 W1 vs W6 chi2 = 5.2 p =0.022
2 (1.8)
43 (39.1)
23 (20.9)
B vs W1 chi2=47 p<0.001 B vs W6 chi2= 19.9 p<0.0001 W1 vs W6 chi2 = 8.7, p =0.0033
Treatment group 1 (10 mg of solifenacin) (n=114) S
11 (10.6)
48 (46.2)
32 (30.8)
B vs W1 chi2=15.8 p<0.001 B vs W6 chi2=5.2 p=0.022 W1 vs W6 NS
2 (1.9)
48 (46.2)
32 (30.8)
B vs W1 chi2=31.1 p<0.001 B vs W1 chi2=23.5 p<0.0001 P1 vs P2 NS
Treatment group 2 (50 mg of mirabegron) (n=104) M
13 (11.4)
38 (33.3)
26 (22.8)
B vs W1 chi2 =32.4 p<0.001 B vs W6 chi2= 12.9 p=<0.0001 W1 vs W6 chi2=5.2 p=0.023
2 (1.8)
32 (28.1)
26 (22.8)
B vs W1 chi2 =57.1 p<0.001 B vs W6 chi2= 31.6 p<0.0001 W1 vs W6 chi2=5.2 p=0.023
Baseline: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 1: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 6: C vs. S (NS); C vs. M (NS); S vs. M (NS). Pharmacological treatment did not modulate the course of these symptoms.
